Targeting CD93 in Infantile Hemangioma: Underlying Mechanisms of Angiogenesis and Therapeutic Intervention

Imagine your body as a bustling city, where blood vessels are the highways delivering oxygen and nutrients to every neighborhood. Sometimes, during early childhood, a construction crew gets a little too excited and builds a massive, tangled web of new roads in one specific spot. This is what doctors call an infantile hemangioma—a common, usually harmless, but sometimes tricky growth that appears as a red birthmark. While these "roadworks" often fix themselves over time, they can leave behind messy scars or permanent bumps, and sometimes the construction crew just won't stop building. Currently, doctors have a favorite tool to slow down this construction: a heart medication called propranolol. It works for many, but not everyone, and it can have side effects like making a child's heart beat too slowly or blood sugar drop too low. Scientists are always on the hunt for a more precise "stop sign" that targets only the overzealous builders without messing up the rest of the city. This is where a molecule called CD93 enters the story. Think of CD93 as a super-charged foreman on the construction site, a protein that tells the building crews to keep laying down new roads. The big question is: if we can find a way to tell this foreman to take a break, can we stop the hemangioma from growing?

This research paper dives deep into that very question, acting like a detective story to see if CD93 is indeed the key to unlocking a new treatment. The scientists started by looking at real samples from children with these growths, specifically during the phase when the tumor is growing fast. They found that CD93 was shouting loudly in these tissues, appearing in huge amounts compared to normal skin or older, shrinking tumors. It was like finding a megaphone in the middle of a construction site. To prove this wasn't just a coincidence, they went into the lab and isolated special "stem cells" from the tumors—let's call them the master builders. When they looked at these master builders, they saw that the ones with the most CD93 were the most energetic, building complex networks of tubes (which mimic blood vessels) much faster than their peers.

To test if CD93 was actually causing this excitement, the researchers played a game of "add and subtract." First, they forced normal cells to make extra CD93. The result? These cells went into overdrive, building tube networks that were longer and more connected, with significantly more junctions and meshes. Then, they did the opposite: they silenced the CD93 gene in the master builders. Suddenly, the construction slowed down; the cells built fewer tubes and shorter networks. To make sure this wasn't just a genetic trick, they also tried a different approach: they used a special antibody (a type of protein that acts like a lock) to block the CD93 foreman. When they blocked CD93, the tube-building ability dropped significantly, proving that this molecule is a critical driver of the growth.

The story didn't stop in the petri dish; the team took their findings to a living model using mice. They created a mini-version of the human growth by injecting the master builder cells under the skin of mice. In the mice where the cells were programmed to overproduce CD93, the blood vessel density skyrocketed to an average of 113.00 vessels per square millimeter, compared to only 67.67 in the control group. That's a massive jump in construction activity. But here is the most exciting part: when they treated the mice with the CD93-blocking antibody, the growth of new blood vessels was crushed. The density of vessels in the treated group plummeted to just 46.36 vessels per square millimeter, while the untreated control group exploded to 184.88 vessels per square millimeter.

The paper suggests that CD93 is a major player in the rapid growth phase of infantile hemangiomas and that blocking it could be a powerful way to stop the tumor from expanding. The researchers found that while CD93 is abundant in the fast-growing phase, it fades away as the tumor naturally shrinks, which makes it a very specific target. However, the authors are careful to note that while their results are strong, they are based on a relatively small number of samples and mouse models. They suggest that CD93 is a promising new target for therapy, but they don't claim it's a cure-all yet. Instead, they propose that targeting this specific "foreman" could offer a safer, more precise alternative to current treatments, potentially sparing children from the side effects of broader medications. The study opens a door to a new way of thinking about how to calm down these overactive construction sites, but it also reminds us that more work is needed to fully understand the complex machinery behind the scenes.